FR2967674B1 - Derives d'heteroarylsulfonamides, leur preparation et leur application en therapeutique humaine - Google Patents

Derives d'heteroarylsulfonamides, leur preparation et leur application en therapeutique humaine

Info

Publication number
FR2967674B1
FR2967674B1 FR1059634A FR1059634A FR2967674B1 FR 2967674 B1 FR2967674 B1 FR 2967674B1 FR 1059634 A FR1059634 A FR 1059634A FR 1059634 A FR1059634 A FR 1059634A FR 2967674 B1 FR2967674 B1 FR 2967674B1
Authority
FR
France
Prior art keywords
preparation
application
human therapeutics
heteroarylsulfonamide
derivatives
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
FR1059634A
Other languages
English (en)
Other versions
FR2967674A1 (fr
Inventor
Passelaigue Elisabeth Dupont
Roy Isabelle Le
Christophe Pignier
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pierre Fabre Medicament SA
Original Assignee
Pierre Fabre Medicament SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pierre Fabre Medicament SA filed Critical Pierre Fabre Medicament SA
Priority to FR1059634A priority Critical patent/FR2967674B1/fr
Priority to TW100140099A priority patent/TWI576106B/zh
Priority to ARP110104287A priority patent/AR083903A1/es
Priority to CN201180055123.XA priority patent/CN103209980B/zh
Priority to US13/822,406 priority patent/US8846930B2/en
Priority to PCT/EP2011/070736 priority patent/WO2012069503A1/fr
Priority to EP11785690.6A priority patent/EP2643318A1/fr
Priority to AU2011333772A priority patent/AU2011333772B2/en
Priority to CA2817531A priority patent/CA2817531A1/fr
Priority to RU2013126251/04A priority patent/RU2582995C2/ru
Priority to JP2013540331A priority patent/JP5837085B2/ja
Priority to NZ610700A priority patent/NZ610700A/en
Priority to MX2013005734A priority patent/MX352396B/es
Priority to BR112013012615A priority patent/BR112013012615A2/pt
Priority to UAA201307746A priority patent/UA109295C2/uk
Priority to MYPI2013001836A priority patent/MY168283A/en
Priority to KR1020137015172A priority patent/KR101838326B1/ko
Publication of FR2967674A1 publication Critical patent/FR2967674A1/fr
Application granted granted Critical
Publication of FR2967674B1 publication Critical patent/FR2967674B1/fr
Priority to MA35892A priority patent/MA34658B1/fr
Priority to IL226495A priority patent/IL226495A/en
Priority to HK14100374.0A priority patent/HK1187345A1/xx
Priority to US14/460,951 priority patent/US9156834B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
FR1059634A 2010-11-23 2010-11-23 Derives d'heteroarylsulfonamides, leur preparation et leur application en therapeutique humaine Active FR2967674B1 (fr)

Priority Applications (21)

Application Number Priority Date Filing Date Title
FR1059634A FR2967674B1 (fr) 2010-11-23 2010-11-23 Derives d'heteroarylsulfonamides, leur preparation et leur application en therapeutique humaine
TW100140099A TWI576106B (zh) 2010-11-23 2011-11-03 雜芳基磺醯胺衍生物、其製備方法以及其於人類治療之用途
ARP110104287A AR083903A1 (es) 2010-11-23 2011-11-17 Derivados de benzooxazol y benzotiazol sulfonamidas, utiles para tratar trastornos del ritmo cardiaco y cancer, composiciones farmaceuticas que los contienen y metodo para prepararlos
UAA201307746A UA109295C2 (uk) 2010-11-23 2011-11-23 Похідні гетероарилсульфонамідів, їх одержання і застосування для лікування людини
PCT/EP2011/070736 WO2012069503A1 (fr) 2010-11-23 2011-11-23 Dérivés d'hétéroarylsulfonamides, leur préparation et leur application en thérapie humaine
EP11785690.6A EP2643318A1 (fr) 2010-11-23 2011-11-23 Dérivés d'hétéroarylsulfonamides, leur préparation et leur application en thérapie humaine
AU2011333772A AU2011333772B2 (en) 2010-11-23 2011-11-23 Derivatives of heteroarylsulfonamides, their preparation and their application in human therapy
CA2817531A CA2817531A1 (fr) 2010-11-23 2011-11-23 Derives d'heteroarylsulfonamides, leur preparation et leur application en therapie humaine
RU2013126251/04A RU2582995C2 (ru) 2010-11-23 2011-11-23 Производные гетероарилсульфонамидов, их получение и применение для лечения человека
JP2013540331A JP5837085B2 (ja) 2010-11-23 2011-11-23 ヘテロアリールスルホンアミド誘導体、それらの製造およびヒト治療におけるそれらの応用
CN201180055123.XA CN103209980B (zh) 2010-11-23 2011-11-23 杂芳基磺酰胺类衍生物,其制备及其在人类治疗中的应用
MX2013005734A MX352396B (es) 2010-11-23 2011-11-23 Derivados de heteroarilsulfonamidas, su preparacion y su aplicacion en terapia humana.
BR112013012615A BR112013012615A2 (pt) 2010-11-23 2011-11-23 derivados de heteroarilsulfonamidas, sua preparação e sua aplicação em terapia humana
US13/822,406 US8846930B2 (en) 2010-11-23 2011-11-23 Derivatives of heteroarylsulfonamides, their preparation and their application in human therapy
MYPI2013001836A MY168283A (en) 2010-11-23 2011-11-23 Derivatives of heteroarylsulfonamides, their preparation and their application in human therapy
KR1020137015172A KR101838326B1 (ko) 2010-11-23 2011-11-23 헤테로아릴술폰아미드 유도체, 이의 제조방법 및 인간치료에서의 용도
NZ610700A NZ610700A (en) 2010-11-23 2011-11-23 Derivatives of heteroarylsulfonamides, their preparation and their application in human therapy
MA35892A MA34658B1 (fr) 2010-11-23 2013-05-13 Dérivés d'hétéroarylsulfonamides, leur préparation et leur application en thérapie humaine
IL226495A IL226495A (en) 2010-11-23 2013-05-21 Derivatives of the Terroylsulfonamides, their preparation and their application in human therapy
HK14100374.0A HK1187345A1 (en) 2010-11-23 2014-01-14 Derivatives of heteroarylsulfonamides, their preparation and their application in human therapy
US14/460,951 US9156834B2 (en) 2010-11-23 2014-08-15 Derivatives of heteroarylsulfonamides, their preparation and their application in human therapy

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR1059634A FR2967674B1 (fr) 2010-11-23 2010-11-23 Derives d'heteroarylsulfonamides, leur preparation et leur application en therapeutique humaine

Publications (2)

Publication Number Publication Date
FR2967674A1 FR2967674A1 (fr) 2012-05-25
FR2967674B1 true FR2967674B1 (fr) 2012-12-14

Family

ID=44246390

Family Applications (1)

Application Number Title Priority Date Filing Date
FR1059634A Active FR2967674B1 (fr) 2010-11-23 2010-11-23 Derives d'heteroarylsulfonamides, leur preparation et leur application en therapeutique humaine

Country Status (20)

Country Link
US (2) US8846930B2 (fr)
EP (1) EP2643318A1 (fr)
JP (1) JP5837085B2 (fr)
KR (1) KR101838326B1 (fr)
CN (1) CN103209980B (fr)
AR (1) AR083903A1 (fr)
AU (1) AU2011333772B2 (fr)
BR (1) BR112013012615A2 (fr)
CA (1) CA2817531A1 (fr)
FR (1) FR2967674B1 (fr)
HK (1) HK1187345A1 (fr)
IL (1) IL226495A (fr)
MA (1) MA34658B1 (fr)
MX (1) MX352396B (fr)
MY (1) MY168283A (fr)
NZ (1) NZ610700A (fr)
RU (1) RU2582995C2 (fr)
TW (1) TWI576106B (fr)
UA (1) UA109295C2 (fr)
WO (1) WO2012069503A1 (fr)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ622505A (en) 2009-06-29 2015-12-24 Agios Pharmaceuticals Inc Therapeutic compounds and compositions
CA2834692A1 (fr) * 2011-05-03 2012-11-08 Agios Pharmaceuticals, Inc. Activateurs de la pyruvate kinase destines a une utilisation therapeutique
CN103764147B (zh) * 2011-05-03 2018-05-22 安吉奥斯医药品有限公司 用于治疗的丙酮酸激酶活化剂
WO2014139144A1 (fr) 2013-03-15 2014-09-18 Agios Pharmaceuticals, Inc. Composés et compositions thérapeutiques
US20160229820A1 (en) * 2013-10-17 2016-08-11 Basf Se Process for preparing substituted isatoic acid anhydride compounds and derivatives thereof
WO2015095111A1 (fr) * 2013-12-18 2015-06-25 Merck Sharp & Dohme Corp. Antagonistes de récepteur d'orexine à base de diazépane
CN104292179A (zh) * 2014-10-19 2015-01-21 湖南华腾制药有限公司 一种2-氯苯并[d]恶唑-5-甲醛的制备方法
FR3029112A1 (fr) * 2014-12-02 2016-06-03 Pf Medicament Dispersion solide a base de derives d'heteroarylsulfonamides a usage pharmaceutique
WO2016201227A1 (fr) 2015-06-11 2016-12-15 Agios Pharmaceuticals, Inc. Procédés d'utilisation d'activateurs de la pyruvate kinase
US10793550B2 (en) * 2017-03-24 2020-10-06 Genentech, Inc. 4-piperidin-n-(pyrimidin-4-yl)chroman-7-sulfonamide derivatives as sodium channel inhibitors
CN107556266B (zh) * 2017-09-12 2021-04-23 华南农业大学 一种2-巯基-4-取代-6-氟苯并噻唑及其制法、应用
TW202031645A (zh) * 2018-10-30 2020-09-01 丹麥商Ｈ 朗德貝克公司 作為Kv3鉀通道激活劑之芳基磺醯基吡咯甲醯胺衍生物
CN113200934B (zh) * 2021-05-18 2022-05-31 郑州大学 含苯并吗啉酮-联苯骨架化合物及其制备方法和应用
CN113912595B (zh) * 2021-10-12 2024-03-15 中国药科大学 一类含有噻唑或噻二唑结构的化合物及其应用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5149700A (en) * 1990-05-30 1992-09-22 American Home Products Corporation Substituted arylsulfonamides and benzamides
DE10128331A1 (de) * 2001-06-12 2002-12-19 Aventis Pharma Gmbh Anthranilsäureamide mit Heteroarylsulfonyl-Seitenkette, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltende pharmazeutische Zubereitungen
ATE430142T1 (de) * 2004-12-09 2009-05-15 Hoffmann La Roche Phenylpiperazin-methanon-derivate
WO2006130986A1 (fr) * 2005-06-09 2006-12-14 Merck Frosst Canada Ltd. Derives d'azacyclohexane comme inhibiteurs de la stearoyl-coenzyme a delta-9 desaturase
CA2621164A1 (fr) * 2005-08-26 2007-03-01 Shionogi & Co., Ltd. Derive ayant une activite agoniste vis-a-vis du ppar
EP2215080A1 (fr) * 2007-10-25 2010-08-11 Boehringer Ingelheim International GmbH Composés de diazépane qui modulent le récepteur cb2
NZ589989A (en) * 2008-06-13 2012-08-31 Bionomics Ltd Novel potassium channel blockers and uses thereof
GB0815781D0 (en) * 2008-08-29 2008-10-08 Xention Ltd Novel potassium channel blockers
CN101503392B (zh) * 2009-03-31 2010-12-29 中国药科大学 芳甲胺类化合物、其制备方法及其医药用途
WO2010130638A1 (fr) * 2009-05-14 2010-11-18 Evotec Ag Composés sulfamides, compositions pharmaceutiques et leurs utilisations
NZ622505A (en) * 2009-06-29 2015-12-24 Agios Pharmaceuticals Inc Therapeutic compounds and compositions

Also Published As

Publication number Publication date
EP2643318A1 (fr) 2013-10-02
FR2967674A1 (fr) 2012-05-25
AU2011333772A1 (en) 2013-06-06
US9156834B2 (en) 2015-10-13
IL226495A0 (en) 2013-07-31
IL226495A (en) 2017-06-29
MX352396B (es) 2017-11-22
BR112013012615A2 (pt) 2016-09-06
JP2014502268A (ja) 2014-01-30
AR083903A1 (es) 2013-04-10
KR20130119943A (ko) 2013-11-01
MY168283A (en) 2018-10-19
HK1187345A1 (en) 2014-04-04
KR101838326B1 (ko) 2018-03-13
MA34658B1 (fr) 2013-11-02
MX2013005734A (es) 2013-08-01
TWI576106B (zh) 2017-04-01
CA2817531A1 (fr) 2012-05-31
CN103209980B (zh) 2015-06-03
UA109295C2 (uk) 2015-08-10
NZ610700A (en) 2014-12-24
WO2012069503A1 (fr) 2012-05-31
US20140357624A1 (en) 2014-12-04
AU2011333772B2 (en) 2016-08-18
JP5837085B2 (ja) 2015-12-24
CN103209980A (zh) 2013-07-17
RU2013126251A (ru) 2014-12-27
TW201225951A (en) 2012-07-01
RU2582995C2 (ru) 2016-04-27
US20130172326A1 (en) 2013-07-04
US8846930B2 (en) 2014-09-30

Similar Documents

Publication Publication Date Title
FR2967674B1 (fr) Derives d'heteroarylsulfonamides, leur preparation et leur application en therapeutique humaine
FR2945534B1 (fr) DERIVES DE CYCLOPENTAL[c]PYRROLE-2-CARBOXYLATES, LEUR PREPARATION ET LEUR APPLICATION EN THERAPEUTIQUE
FR2949470B1 (fr) Derives anticancereux, leur preparation et leur application therapeutique
FR2963007B1 (fr) Derives anticancereux, leur preparation et leur application therapeutique
FR2933700B1 (fr) Derives de pyridino-pyridinones, leur preparation et leur application en therapeutique
FR2953520B1 (fr) Derives de diphenyl-pyrazolopyridines, leur preparation et leur application en therapeutique
FR2911604B1 (fr) Derives de n-(heteroaryl-1h-indole-2-carboxamides, leur preparation et leur application en therapeutique
FR2962438B1 (fr) Derives d'indolizines, procedes de preparation et application en therapeutique
FR2948939B1 (fr) Derives de 2h pyridazin-3-ones, leur preparation et leur application en therapeutique humaine
FR2915199B1 (fr) Derives de triazolopyridine-carboxamides et triazolopyrimidine-carboxamides, leur preparation et leur application en therapeutique.
FR2943669B1 (fr) Derives de nicotinamide,leur preparation et leur application en therapeutique
FR2952934B1 (fr) Derives de pyridino-pyridinones, leur preparation et leur application en therapeutique
FR2941696B1 (fr) Derives d'azaspiranyl-alkylcarbamates d'heterocycles a 5 chainons, leur preparation et leur application en therapeutique
FR2954943B1 (fr) Derives de pyridino-pyridinones arylsulfonamides, leur preparation et leur application en therapeutique
FR2917412B1 (fr) Derives de 7-alkynyl, 1,8-naphthyridones, leur preparation et leur application en therapeutique
FR2945533B1 (fr) Derives de cyclopenta°c!pyrrolyl-alkylcarbamates d'heterocycles a 5 chainons, leur preparation et leur application en therapeutique
FR2917413B1 (fr) Derives de 7-alkynyl-1,8-naphthyridones, leur preparation et leur application en therapeutique
FR2927625B1 (fr) Nouveaux derives de 3-aminoalkyl-1,3-dihydro-2h-indol-2-one, leur preparation et leur application en therapeutique
FR2958935B1 (fr) Derives d'heterocycles azotes, leur preparation et leur application en therapeutique humaine
FR2963005B1 (fr) Derives d'oxadiazoles et de pyridazines, leur preparation et leur application en therapeutique
FR2940284B1 (fr) Derives de 6-cycloamino-2,3-di-pyridinyl-imidazo°1,2-b!- pyridazine,leur preparation et leur application en therapeutique
FR2925901B1 (fr) DERIVES DE N-HETEROCYCLIQUE-IMIDAZO°1,2-a!PYRIDINE-2- CARBOXAMIDES, LEUR PREPARATION ET LEUR APPLICATION EN THERAPEUTIQUE
FR2948369B1 (fr) Derives d'uree de tetrahydroquinoxaline, leur preparation et leur application en therapeutique
FR2925903B1 (fr) DERIVES 6-HETEROCYCLIQUE-IMIDAZO°1,2-a!PYRIDINE-2- CARBOXAMIDES, LEUR PREPARATION ET LEUR APPLICATION EN THERAPEUTIQUE
FR2948370B1 (fr) Derives d'uree de tetrahydroquinoxaline, leur preparation et leur application en therapeutique

Legal Events

Date Code Title Description
PLFP Fee payment

Year of fee payment: 6

PLFP Fee payment

Year of fee payment: 7

PLFP Fee payment

Year of fee payment: 8